TW200635899A - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
TW200635899A
TW200635899A TW094145875A TW94145875A TW200635899A TW 200635899 A TW200635899 A TW 200635899A TW 094145875 A TW094145875 A TW 094145875A TW 94145875 A TW94145875 A TW 94145875A TW 200635899 A TW200635899 A TW 200635899A
Authority
TW
Taiwan
Prior art keywords
chemical compounds
manufacture
relates
cancer
activity
Prior art date
Application number
TW094145875A
Other languages
Chinese (zh)
Inventor
Lynsie Almeida
Brian Aquila
Don Cook
Scott Cowen
Les Dakin
Jayachandran Ezhuthachan
Stephanos Ioannidis
John Lee
Stephen Lee
Paul Dermot Lyne
Timothy Pontz
David Scott
Mei Su
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200635899A publication Critical patent/TW200635899A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
TW094145875A 2004-12-22 2005-12-22 Chemical compounds TW200635899A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63917704P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
TW200635899A true TW200635899A (en) 2006-10-16

Family

ID=36602125

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094145875A TW200635899A (en) 2004-12-22 2005-12-22 Chemical compounds

Country Status (3)

Country Link
AR (1) AR053992A1 (en)
TW (1) TW200635899A (en)
WO (1) WO2006067445A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100857312B1 (en) 2004-01-28 2008-09-05 미쓰이 가가쿠 가부시키가이샤 Amide derivatives, process for preparation thereof and use thereof as insecticide
EP3466953B1 (en) 2005-12-13 2021-02-03 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
BRPI0620362A2 (en) * 2005-12-22 2012-07-03 Astrazeneca Ab compound or a pharmaceutically acceptable salt thereof, use thereof, methods for producing a csf-1r kinase inhibitory effect on a warm-blooded animal, for producing an anti-cancer effect on a warm-blooded animal and for treating disease, and pharmaceutical composition
FR2903107B1 (en) 2006-07-03 2008-08-22 Sanofi Aventis Sa IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2903105A1 (en) 2006-07-03 2008-01-04 Sanofi Aventis Sa 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP2468717B1 (en) 2006-10-27 2013-11-20 Bristol-Myers Squibb Company Heterocyclic Amide Compounds Useful as Kinase Inhibitors
CL2008000191A1 (en) 2007-01-25 2008-08-22 Astrazeneca Ab COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER.
SI2173752T2 (en) 2007-06-13 2022-09-30 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
JP5501227B2 (en) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2692153A1 (en) 2007-06-27 2009-01-08 Richard W. Heidebrecht, Jr. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EP2265574A1 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
MX2011012353A (en) 2009-05-22 2011-12-14 Incyte Corp N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.
AR076920A1 (en) 2009-05-22 2011-07-20 Incyte Corp 3- (4- (7H-PIRROLO (2,3-D) PIRIMIDIN-4-IL) -1H-PIRAZOL-1-IL) OCTANO-O HEPTANO - NITRILE AS JAK INHIBITORS
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
AR081315A1 (en) 2010-03-10 2012-08-08 Incyte Corp HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CN103002875B (en) 2010-05-21 2016-05-04 因塞特控股公司 Topical formulations of JAK inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
BR112013012502A2 (en) 2010-11-19 2019-03-06 Incyte Corporation substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors
PL2686302T3 (en) 2011-03-16 2017-01-31 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
MX344479B (en) 2011-06-20 2016-12-16 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors.
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
US8629274B2 (en) 2011-12-21 2014-01-14 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201920090A (en) 2012-08-28 2019-06-01 愛爾蘭商健生科學愛爾蘭無限公司 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
UA120834C2 (en) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Sustained-release dosage forms of ruxolitinib
SI2961732T1 (en) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
RS58547B1 (en) 2013-03-06 2019-05-31 Incyte Holdings Corp Processes and intermediates for making a jak inhibitor
MX353412B (en) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
JP6322280B2 (en) 2013-05-14 2018-05-09 アクティブ バイオテック エイビー N- (heteroaryl) sulfonamide derivatives useful as S-100 inhibitors
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014353893A1 (en) * 2013-11-25 2016-06-09 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9908872B2 (en) * 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX2016009449A (en) 2014-02-05 2016-10-13 Novira Therapeutics Inc Combination therapy for treatment of hbv infections.
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SI3110409T1 (en) 2014-02-28 2018-11-30 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3209648B1 (en) 2014-10-22 2020-03-11 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (en) 2015-07-06 2022-04-28 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
LT3426243T (en) 2016-03-09 2021-08-10 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
BR112018071048A2 (en) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinations and methods comprising a capsid assembly inhibitor
WO2018041122A1 (en) 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
SI3570834T1 (en) 2017-01-11 2022-05-31 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
CN110573500B (en) * 2017-05-24 2020-12-08 上海和誉生物医药科技有限公司 N- (nitrogen heterocyclic aryl) lactam-1-formamide derivative and preparation method and application thereof
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111032040B (en) 2017-08-07 2023-08-29 罗丹疗法公司 Bicyclic inhibitors of histone deacetylase
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
KR20210018203A (en) 2018-03-30 2021-02-17 인사이트 코포레이션 Treatment of purulent sweating with JAK inhibitors
MX2020014165A (en) 2018-06-29 2021-03-09 Syngenta Participations Ag Pesticidally active azole-amide compounds.
BR112021015618A2 (en) 2019-02-22 2021-10-05 Janssen Sciences Ireland Unlimited Company AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES
JP2022523434A (en) 2019-03-08 2022-04-22 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト Pesticide-active azole-amide compound
EP3941915A1 (en) 2019-03-20 2022-01-26 Syngenta Crop Protection AG Pesticidally active azole amide compounds
CN113597426A (en) 2019-03-22 2021-11-02 先正达农作物保护股份公司 N- [1- (5-bromo-2-pyrimidin-2-yl-1, 2, 4-triazol-3-yl) ethyl ] -2-cyclopropyl-6- (trifluoromethyl) pyridine-4-carboxamide derivatives and related compounds as insecticides
UY38623A (en) 2019-03-29 2020-10-30 Syngenta Crop Protection Ag DIAZINE-AMIDE COMPOUNDS ACTIVE AS PESTICIDES
MX2021012162A (en) 2019-04-05 2021-11-03 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds.
CN113795486A (en) 2019-05-06 2021-12-14 爱尔兰詹森科学公司 Amide derivatives for the treatment of HBV infection or HBV-induced diseases
CR20220090A (en) 2019-08-08 2022-08-24 Les Laboratories Servier A method for preparing ivosidenib and an intermediate thereof
CN114269732A (en) 2019-08-23 2022-04-01 先正达农作物保护股份公司 Pesticidally active pyrazine-amide compounds
WO2021122645A1 (en) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
EP4110766A1 (en) 2020-02-27 2023-01-04 Syngenta Crop Protection AG Pesticidally active diazine-bisamide compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202300142A (en) * 2021-05-24 2023-01-01 大陸商上海和譽生物醫藥科技有限公司 Acid salt of crystalline csf-1r inhibitor, and preparation method therefor and use thereof
WO2022258481A1 (en) 2021-06-09 2022-12-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
CN115724791A (en) * 2022-10-10 2023-03-03 安徽金禾化学材料研究所有限公司 Preparation method of 2-methyl-3-nitro-5-aminopyridine
CN115611806A (en) * 2022-11-08 2023-01-17 江苏中旗科技股份有限公司 Preparation method of 4-trifluoromethyl-3-cyanopyridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
SK13132001A3 (en) * 1999-03-17 2002-02-05 Astrazeneca Ab Amide derivatives, method for their preparation, pharmaceutical composition containing same and the use thereof
GB0414631D0 (en) * 2004-06-30 2004-08-04 Reckitt Benckiser Nv Packaging for moisture sensitive material

Also Published As

Publication number Publication date
WO2006067445A2 (en) 2006-06-29
AR053992A1 (en) 2007-05-30
WO2006067445A3 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
TW200635899A (en) Chemical compounds
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
MX2007008924A (en) Chemical compounds.
TW200621259A (en) Chemical compounds
TW200736234A (en) Chemical compounds
TW200621730A (en) Chemical compounds
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
WO2007113558A8 (en) Quinazolinone derivatives having b-raf inhibitory activity
MX2009004908A (en) Chemical compounds.
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
MX2009004906A (en) Heterocyclyc sulfonamides having edg-i antagonistic activity.
MX2010007523A (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents.
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
NO20070199L (en) Substituted quinazolones as anti-cancer agents
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TW200621762A (en) Novel compounds
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
SG148177A1 (en) Novel cis-imidazolines
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
IL180136A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
TW200604182A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them